Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VYR-2020 (Vyripharm Biopharmaceuticals)
- Development stage
- Preclinical
- Lead developer
- Vyripharm Biopharmaceuticals
- Modality
- Small Molecules
01
Overview
VYR-2020 is a preclinical antiviral small molecule developed by Vyripharm Biopharmaceuticals for the treatment and diagnosis of viral infections, specifically targeting coronaviruses such as SARS-CoV-2 (COVID-19), SARS-CoV, and MERS-CoV. It is designed as part of a multi-component theranostic platform that integrates nuclear medicine imaging with antiviral therapy. The platform often utilizes VYR-2020 in conjunction with a CB1 antagonist (such as VYR-206 or a related analogue) to monitor disease progression and therapeutic efficacy through a radiotherapeutic regimen. Vyripharm partnered with Regis Technologies for cGMP manufacturing to facilitate the transition from preclinical studies to first-in-human clinical trials.
- Other names
- Anti-viral therapeutic formulationVyripharm coronavirus antiviral
Beyond the preview
Go deeper on VYR-2020 (Vyripharm Biopharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VYR-2020 (Vyripharm Biopharmaceuticals).